Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Issues And Trends In Healthcare Delivery System01:29

Issues And Trends In Healthcare Delivery System

The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Upstream Processing01:27

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FDA approves Galafold, a triumph for Amicus.

Nature biotechnology·2018
Same author

Biotech startups woo increasing numbers of crowdfunders.

Nature biotechnology·2017
Same author

From the bottom of a DNA cocktail glass.

Nature biotechnology·2013
Same author

Court injunction threatens clinical data transparency push.

Nature biotechnology·2013
Same author

AstraZeneca juggernaut heads for Cambridge.

Nature biotechnology·2013
Same author

No-fee university licenses spur biotech partnerships.

Nature biotechnology·2013

Related Experiment Video

Updated: May 8, 2026

Interview: Bioreactors and Surfaced-Modified 3D-Scaffolds for Stem Cell Research
08:06

Interview: Bioreactors and Surfaced-Modified 3D-Scaffolds for Stem Cell Research

Published on: May 21, 2008

Biotechs to tap into Horizon 2020's $93 billion

Nuala Moran

    Nature Biotechnology
    |September 12, 2013
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Development of New Therapeutic Applications Using Microfluidics
    08:56

    Development of New Therapeutic Applications Using Microfluidics

    Published on: October 1, 2007

    Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
    16:26

    Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

    Published on: August 20, 2007

    Related Experiment Videos

    Last Updated: May 8, 2026

    Interview: Bioreactors and Surfaced-Modified 3D-Scaffolds for Stem Cell Research
    08:06

    Interview: Bioreactors and Surfaced-Modified 3D-Scaffolds for Stem Cell Research

    Published on: May 21, 2008

    Development of New Therapeutic Applications Using Microfluidics
    08:56

    Development of New Therapeutic Applications Using Microfluidics

    Published on: October 1, 2007

    Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
    16:26

    Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

    Published on: August 20, 2007